Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arcus Biosciences (RCUS)

Arcus Biosciences closes $269.7 million share sale of 16,428,572 common shares

Neutral Impact 3 of 5 financing

Arcus Biosciences sold 16,428,572 shares of common stock at a public offering price of $17.50 per share, including the full exercise of the underwriters' option, and the offering closed on October 23, 2026. The company received net proceeds of approximately $269.7 million after underwriting discounts, commissions and estimated offering expenses. Shareholders face a larger share count, and the filing does not describe how the proceeds will be used.

Key points

  • Public offering price of $17.50 per share; underwriters agreed to buy the shares from the company at $16.45 per share.
  • Total of 16,428,572 shares issued, including 2,142,857 shares from the underwriters' option exercised in full.
  • Offering closed October 23, 2026, with net proceeds of approximately $269.7 million.
  • Underwriters were Jefferies LLC, Leerink Partners LLC and TD Securities (USA) LLC, under Form S-3 Registration No. 333-293750.

The filing

CompanyArcus Biosciences (RCUS)
Form8-K, current report
Filed with the SECOct 23, 2026, 4:12 PM ET
Accession number0001724521-26-000050

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.